Why the study?
Very late restenosis within the Magmaris magnesium bioresorbable scaffold had not been previously published, likely due to 95% scaffold resorption occurring at 12 months.
Answers are grounded in this paper and cite their sources.
This case highlights the occurrence of very late in-scaffold restenosis with the Magmaris bioresorbable scaffold, a phenomenon previously unpublished for this device.
Magnesium Bioresorbable Scaffold (Magmaris, Biotronik) is a device with promising outcomes at 24 months of follow up. Previous studies with first generation, everolimus-eluting Bioresorbable Vascular Scaffold (Absorb, Abbott) showed that very late restenosis seems to be attributed to pure intrascaffold tissue growth but very late. Magmaris very late restenosis has not been previously published, probably because of the 95% of resorption at 12 months. We present in-scaffold very late restenosis within Magmaris, with Optical Coherence Tomography, highlighting mechanism of degradation and in scaffold "neo-tissue" growth.
No takes yet. Share an insight, caveat, or question.
Bayón et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: